Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 25: Short-Term Anticoagulation Vs DAPT for Preventing Device Thrombosis Following LAAC
Author(s): Josep Rodés-Cabau Added: 2 weeks ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device… View more

Anticoagulation

Imaging & Diagnostics
Prevention: What's New at HFA 2025?
Author(s): Harriette Van Spall , Maja Cikes Added: 5 months ago
ESC HF 25 - Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Maja Cikes (University Hospital Centre Zagreb, HR) for an insightful wrap up of the novel data concerning preventive cardiology that was presented at 2025's Heart Failure Congress.Trials discussed include:REDICAE (00:42)FINEARTS HF (02:27)CRISPR Gene Editing with Nexiguran Ziclumeran (05:53)HELIOS B (07:12)RESHAPE… View more

Heart Failure
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 1 year ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Guidelines & Statements

Prevention & Chronic Conditions
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 5 months ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 3 days ago
Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview Questions:Can you provide an overview… View more

Heart Failure
ESC HF 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 5 months ago
ESC HF 25 - SCD-PROTECT zeigt hohes Risiko für plötzlichen Herzstillstand (SCA) und plötzlichen Herztod (SCD) während der frühen medikamentösen Therapieoptimierung bei reduzierter LVEF bei Patienten mit neu diagnostizierter nicht-ischämischer Kardiomyopathie oder MI/KHK.Prof Johann Bauersachs (Medizinische Hochschule Hannover, Hannover, DE) diskutiert Ergebnisse aus dem SCD-PROTECT studie, einer… View more

Heart Failure

MI/ACS
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Author(s): Roberta Esposito , Pierantonio Menna , Emanuela Salvatorelli , et al Added: 1 month ago

CV Disease in Special Populations

Prevention & Chronic Conditions
ESC 25: The HI-PRO Trial
Author(s): Gregory Piazza Added: 2 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more

Anticoagulation

Vascular Disease and Surgery